Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 26,323.0 | 25,979.0 | 25,424.0 | 23,362.0 | 23,747.0 | 22,849.0 | 22,991.0 | 21,662.0 |
| Revenue growth | 1.3% | 2.2% | 8.8% | -1.6% | 3.9% | -0.6% | 6.1% | 8.0% |
| Cost of goods sold | 6,406.0 | 6,454.0 | 6,159.0 | 4,356.0 | 4,101.0 | 4,069.0 | 4,162.0 | 4,227.0 |
| Gross profit | 19,917.0 | 19,525.0 | 19,265.0 | 19,006.0 | 19,646.0 | 18,780.0 | 18,829.0 | 17,435.0 |
| Gross margin | 75.7% | 75.2% | 75.8% | 81.4% | 82.7% | 82.2% | 81.9% | 80.5% |
| Selling, general and administrative | 5,414.0 | 5,368.0 | 5,730.0 | 5,150.0 | 5,332.0 | 4,870.0 | 5,062.0 | 4,846.0 |
| Research and development | 4,434.0 | 4,819.0 | 4,207.0 | 4,116.0 | 3,737.0 | 3,562.0 | 3,840.0 | 4,070.0 |
| EBITA | 12,166.0 | 10,239.0 | 11,939.0 | 11,074.0 | 11,563.0 | 11,273.0 | 11,294.0 | 9,870.0 |
| EBITA margin | 46.2% | 39.4% | 47.0% | 47.4% | 48.7% | 49.3% | 49.1% | 45.6% |
| Amortization of intangibles | 2,600.0 | 2,600.0 | 2,800.0 | 1,400.0 | 1,300.0 | 1,300.0 | 1,500.0 | 1,400.0 |
| EBIT | 9,566.0 | 7,639.0 | 9,139.0 | 9,674.0 | 10,263.0 | 9,973.0 | 9,794.0 | 8,470.0 |
| EBIT margin | 36.3% | 29.4% | 35.9% | 41.4% | 43.2% | 43.6% | 42.6% | 39.1% |
| Pre-tax income | 7,346.0 | 6,701.0 | 8,133.0 | 9,138.0 | 9,545.0 | 9,597.0 | 9,163.0 | 7,978.0 |
| Income taxes | 794.0 | 808.0 | 869.0 | 1,296.0 | 1,151.0 | 7,618.0 | 1,441.0 | 1,039.0 |
| Tax rate | 10.8% | 12.1% | 10.7% | 14.2% | 12.1% | 79.4% | 15.7% | 13.0% |
| Net income | 6,552.0 | 5,893.0 | 7,264.0 | 7,842.0 | 8,394.0 | 1,979.0 | 7,722.0 | 6,939.0 |
| Net margin | 24.9% | 22.7% | 28.6% | 33.6% | 35.3% | 8.7% | 33.6% | 32.0% |
| |
| Diluted EPS | $12.11 | $10.28 | $12.31 | $12.88 | $12.62 | $2.69 | $10.24 | $9.06 |
| Shares outstanding (diluted) | 541.0 | 573.0 | 590.0 | 609.0 | 665.0 | 735.0 | 754.0 | 766.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|